Completed PHASE1 INTERVENTIONAL 1-arm NCT01410968

A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma

Sponsor: Carolyn Britten

Interventions vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells

Updated 6 times since 2017 Last updated: Dec 8, 2016 Started: Aug 31, 2011 Primary completion: Nov 30, 2013 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01410968, this PHASE1 trial focuses on Metastatic Pancreatic Cancer and remains completed. Sponsored by Carolyn Britten, it has been updated 6 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Carolyn Britten
Oncovir, Inc.

Data source: Medical University of South Carolina

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charleston, United States